524735 logo

Hikal Limited Stock Price

BSE:524735 Community·₹30.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

524735 Share Price Performance

₹244.75
-95.95 (-28.16%)
₹300.00
Fair Value
₹244.75
-95.95 (-28.16%)
18.4% undervalued intrinsic discount
₹300.00
Fair Value
Price ₹244.75
AnalystConsensusTarget ₹300.00

524735 Community Narratives

·
Fair Value ₹300 18.4% undervalued intrinsic discount

Global Supply Chain Diversification Will Unlock Indian CRAMS Potential

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
₹300
18.4% undervalued intrinsic discount
Profit Margin
9.3%
Future PE
23.09x
Price in 2029
₹425.88

Trending Discussion

Updated Narratives

524735 logo

524735: Dividend And Board Changes Will Support Future Upside Potential

Fair Value: ₹300 18.4% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Reasonable growth potential with adequate balance sheet.

1 Risk
2 Rewards

Hikal Limited Key Details

₹17.1b

Revenue

₹7.6b

Cost of Revenue

₹9.5b

Gross Profit

₹10.0b

Other Expenses

-₹488.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-3.96
55.52%
-2.85%
56.8%
View Full Analysis

About 524735

Founded
1988
Employees
2062
CEO
Sameer Hiremath
WebsiteView website
www.hikal.com

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Recent 524735 News & Updates

Narrative Update Jun 22

524735: Dividend And Board Changes Will Support Future Upside Potential

Analysts have trimmed their price target for Hikal from ₹320 to ₹300, reflecting updated assumptions for slightly lower revenue growth, a softer profit margin outlook, and a higher future P/E multiple. What’s in the News for Hikal Hikal has scheduled a Special or Extraordinary Shareholders Meeting on July 4, 2026, to be conducted via postal ballot in India.
Narrative Update Jun 04

524735: Board Actions And Dividend Decision Will Support Future Upside Potential

Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.

Recent updates

No updates